Delivery Hero Shares Jump on Uber Takeover Offer at 33 Per Share
Snowflake Stock Surges 36 on Earnings Beat and 6 Billion AWS Expansion Plan
SP 500 Earnings Surge Historically Signals Caution for Investors
Micron Stock Hits Major Milestone as UBS Highlights Strong Memory Chip Demand
Forbes Reveals Top 10 Cryptocurrencies as of May 28 2026
Biotech and Pharma Stocks Decline Amid Rotation Into Energy Sector
VVV Q1 2026 Earnings EPS Surges 18 Above Estimates Stock Climbs
Fluor Corporation FLR Q1 2026 Earnings EPS Falls Sharply Below Estimates Despite Modest Share Gain
Sunrun RUN Q1 2026 Earnings Solar Leader Posts Record EPS Surprise Shares Rally
High Tide Inc Q1 2026 Earnings EPS Beat of 300 Fails to Lift Shares Amid Missing Revenue Disclosure
ALRM Q1 2026 Earnings EPS Beats Estimates Stock Edges Higher
POWWP Q1 2026 Earnings Preferred Stock Delivers Positive Surprise with EPS Beat
Aclarion Inc Warrant ACONW Declines Sharply Testing AllTime Low Territory
Stereotaxis Inc STXS Shows Modest Uptick Testing Key Resistance Levels
ITHAX Acquisition Corp III ITHA Edges Lower as SPAC Trades Near Trust Value
Actelis Networks ASNS Inches Higher at 009 as Penny Stock Holds Key Support
Waterstone Financial WSBF Holds Steady Near Support Modest Uptick Signals Consolidation
USIran Standoff Deepens After Trump Rejects Counteroffer Raising Risks for Global Energy Markets
Intergroup Corporation INTG Q1 2026 Earnings Positive EPS as Stock Advances Despite Sparse Disclosure
Webull Warrants BULLW Slide 95 as Selling Pressure Intensifies Near Key Support
XLO Q1 2026 Earnings Narrower Loss and Positive Stock Reaction Signal Progress
GPK Q1 2026 Earnings EPS Surges 56 Above Estimates Stock Jumps 515
TLYS Q1 2026 Earnings Earnings Surprise with 165 EPS Beat
Ionis Pharmaceuticals Q1 2026 Earnings EPS Beat Driven by Cost Discipline Stock Holds Steady
SLSN Q1 2026 Earnings Loss Per Share of 001 as Shares Decline 234
PMCB Q1 2026 Earnings PreRevenue Biotech Reports Negative EPS Stock Rises on Potential Pipeline Progress
ASND Q1 2026 Earnings EPS Misses Estimates as Ascendis Pharma Navigates Cost Pressures